At-home saliva test could speed FSHD diagnoses

A new at-home saliva test for facioscapulohumeral dystrophy, or FSHD, could make diagnosis easier and help identify at-risk family members sooner. Researchers and advocates say improved testing is pushing incidence estimates higher, with more Australians now believed to be affected than previously thought. Why it matters: - FSHD is one of the most common forms of muscular dystrophy, and earlier testing can help people get a diagnosis before years of unexplained weakness. - Better access to testing also helps identify relatives who may be at risk and opens the door to research participation and future treatment trials. - The Foundation says current incidence is estimated at 1 in 7,500 people, up from older estimates of 1 in 20,000. - That estimate translates to more than 3,000 Australians at risk. What happened: - Research from the University of Nevada, funded by FSHD Global Research Foundation in Sydney, describes innovations behind an at-home saliva test for FSHD. - The test is currently for research use only. - World FSHD Awareness Day falls on Saturday, June 20. - FSHD Global Research Foundation says the new testing approach is helping drive a rise in diagnoses as access improves. The details: - FSHD, or facioscapulohumeral dystrophy, is a muscle-wasting disease that can affect the ability to walk, talk, smile, blink or eat. - Muscle weakness in FSHD often develops asymmetrically, such as in one arm or one leg. - Symptoms can appear years before a formal diagnosis. - Some people do not realize they are losing muscle function because the weakness develops slowly. - The research is led by Dr. Takako Jones at the University of Nevada. - Jones said the method improves sensitivity and broadens the definition of genetic FSHD to better match clinical FSHD. - Jones said the approach can help identify people at risk in affected families and in large population studies. - Emma Weatherley, chief executive of FSHD Global Research Foundation, said many people were previously misdiagnosed and are now being identified correctly as testing improves. - Weatherley said the foundation has received no government funding for this work. - The foundation says people who join its Cure FSHD patient registry answer questions that may determine whether they qualify for a free at-home saliva test kit. - Registry participants may also be offered further testing, including a 3D MRI muscle scan. - The foundation says registry participation helps improve understanding of FSHD in the population and advances research worldwide. - The foundation says it has spent 15 years supporting research, diagnostics and advocacy with little awareness in the medical community. - The foundation says it has already brought two clinical trials with potential treatments to Australia and expects more. - Australians who want to join those trials need testing and a validated diagnosis. - More information is available at the foundation’s website . - The research publication is available at the saliva test study . Between the lines: - The rising incidence estimate appears tied to better detection rather than a sudden surge in disease prevalence. - The combination of low-cost at-home testing and registry enrollment could make it easier to find undiagnosed cases that traditional systems miss. - The foundation’s push for awareness and testing also underscores a funding gap, since it says the work has moved ahead without government support. What’s next: - The at-home saliva test remains limited to research use, so broader clinical adoption will depend on further validation. - More testing could expand the number of confirmed cases and increase eligibility for future clinical trials in Australia. - The foundation is continuing its registry, testing efforts and advocacy ahead of World FSHD Awareness Day.